Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 549-555

  Kirkwood, L C ^a   Nation, R L ^a   Somogyi, A A ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CYP2D6; CYP3A; Dihydrocodeine; Human liver microsomes; MEtabolism

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; DIHYDROCODEINE; DIHYDROMORPHINE; ERYTHROMYCIN; FURAFYLLINE; MEPHENYTOIN; QUINIDINE; QUININE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

EID: 0030661633     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00626.x     Document Type: Article

References (27)

1. Hufschmid E, Theurillat R, Martin U, Thormann W. Exploration of the metabolism of dihydrocodeine via determination of its metabolites in human untie using micellar electrokinetic capillary chromatography. J Chromatogr B 1995; 668: 159-170.
2. Fromm MF, Hofmann U, Griese EU, Mikus G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 m humans. Clin Pharmacol Ther 1995; 58: 374-382.
3. Creese I, Snyder SH. Receptor binding and pharmacological activity of opiates in the guinea-pig intestine. J Pharmacol Exp Ther 1975; 194: 205-219.
4. Kirkwood LC, Venning MG, Nation RL, et al. Comparative activity of dihydrocodeine and its metabolites in the electrically stimulated guinea-pig isolated ileum. Pharm Sci 1995; 1: 573-575.
5. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
6. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
7. Daly AK, Brockmöller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
8. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994; 38: 243-248.
9. de Morais SMF, Goldstein JA, Xie H-G, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
10. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P-450 bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447-5454.
11. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
12. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370-2378.
13. Segel IH. Enzyme kinetics, First Edition, New York: John Wiley & Sons, 1975: 196-198.
14. Kirkwood LC, Nation RL, Reynolds GD, Somogyi AA, Sansom LN. Oxidative metabolism of dihydrocodeine in Dark-Agouti and Sprague-Dawley rat liver microsomes. Pharm Sci 1996; 2: 1-5.
15. Newton DJ, Wang RW, Lu AYH. Cytochrome P-450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
16. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990; 45: 1-38.
17. Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P-450 active site. Biochemistry 1994; 33: 6450-6455.
18. Caraco Y, Tateishi T, Guengerich FP, Wood AJJ. Microsomal codeine N-demethylation: cosegregation with cytochrome P-4503A4 activity. Drug Metab Dispos 1996; 24: 761-764.
19. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3: 197-204.
20. Liu Z, Mortimer Ö, Smith CAD, Wolf CR, Rane A. Evidence for a role of cytochrome P-450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 1995; 39: 77-80.
21. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P-450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
22. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
23. Kobayashi S, Murray S, Watson D, et al. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989; 38: 2795-2799.
24. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 db1/bufl). Biochem Biophys Res Commun 1988; 152: 411-416.
25. Desmeules J, Gascon M, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41: 23-26.
26. Sindrup SH, Arendt-Nielsen L, Brosen K, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992; 42: 587-592.
27. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450 db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-8260.